Igor Bussel, MD
Glaucoma Specialist · Fullerton, CANPI 1699193367
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,424 of the $6,437 with a category attached, or 68.7%. 18 manufacturers reported payments, led by GSK at 30.9% of the total. Reporting peaked in 2021 at $2,844 and has fallen 80.3% since, to $559 in 2025.
Across 106 payments — averaging $60.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$1K
- Alcon$788
- Sight Sciences, Inc.$421
- Glaukos Corporation$324
- Aerie Pharmaceuticals, Inc.$210
- plus $1K from 12 others
What the payments were for
- Consulting fees$1,95030%
- Food & beverage$4,42469%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 2 | $1,989 |
| AbbVie(2 entities) | 32 | $1,394 |
| Alcon | 13 | $788 |
| Sight Sciences, Inc. | 16 | $421 |
| Glaukos Corporation | 7 | $324 |
| Aerie Pharmaceuticals, Inc. | 5 | $210 |
| Nova Eye, Inc. | 1 | $176 |
| Bausch & Lomb Americas Inc. | 9 | $171 |
| NEW World Medical,inc. | 1 | $155 |
| Ivantis, Inc | 1 | $140 |
| Mallinckrodt Enterprises LLC | 1 | $123 |
| Harrow Eye, LLC | 2 | $122 |
| Novartis | 1 | $110 |
| Sun Pharmaceutical Industries Inc. | 4 | $84 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $83 |
| Thea Pharma Inc. | 3 | $70 |
| Oyster Point Pharma, Inc. | 2 | $62 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BLENREP$1,950
- XEN GLAUCOMA TREATMENT SYSTEM$359
- XEN$250
- AcrySof$168
- Ahmed Glaucoma Valve$155
- Kahook Dual Blade$155
- Hydrus Microstent$140
- Rocklatan$125
- Rhopressa$125
- ACTHAR$123
- iStent inject W$104
- KXL System$104
- Photrexa$104
- OMNI$104
How this compares
$6,437 in reported general payments places this provider in the 60th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 119 | $49,196 |
| VyzultaLatanoprostene Bunod | 77 | $38,975 |
| LumiganBimatoprost | 77 | $37,822 |
| RocklatanNetarsudil Mesylat/Latanoprost | 77 | $30,821 |
| RestasisCyclosporine | 22 | $18,885 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 51 | $12,789 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 56 | $8,731 |
| Prednisolone Acetate | 229 | $8,662 |
| Brimonidine Tartrate | 136 | $7,422 |
| Travoprost | 29 | $5,958 |
| Alphagan PBrimonidine Tartrate | 12 | $5,817 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 291 | $5,719 |
| Latanoprost | 590 | $5,663 |
| Methazolamide | 36 | $5,448 |
| TafluprostTafluprost/Pf | 21 | $3,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $210 | $80,017196 claims |
| AbbVieLumigan, Restasis, Alphagan P | $1,394 | $62,524111 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $171 | $38,97577 claims |
| AlconSimbrinza | $788 | $12,78951 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Fullerton
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.